Parameter
| Biomarker | EBV-DNA | Full name | Epstein-Barr virus DNA | Molecular Type | Nucleic acid (viral DNA) |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Prognostic assessment (EBV-positive cHL) |
| Disease | Non-Hodgkin Lymphoma (NHL) | Disease Subtypes | / | ||
| Organ | Blood and lymphoid tissue | Test Sample / Technology Platform | blood plasma （qPCR） | ||
| Pathobiological Mechanisms | EBV infection is associated with the onset of chronic lymphocytic leukemia (cHL), and plasma EBV-DNA levels reflect viral activity and tumor burden. | ||||
| Clinical Availability Status | Clinical validation phase: Non-invasive detection of EBV-positive chronic lymphocytic leukemia (cHL) indicates disease activity and prognosis. | ||||
| Notes and Dynamics | Combined with cfDNA grouping, patients with EBV-and SOCS1 mutations have a higher risk of treatment failure. | ||||